In The News

You are here

Dr. Knopman Keynotes on Cerebrovascular Surgery

Dr. Jared Knopman, Weill Cornell Medicine

Dr. Jared Knopman was the keynote speaker at the 14th annual “Current Techniques in the Treatment of Cranial and Spinal Disorders” Symposium, held Saturday, October 21, 2017, at the Omni Interlocken Resort in Broomfield, Colorado. The CME conference was jointly provided by the American Association of Neurological Surgeons (AANS) and the Justin Parker Neurological Institute.

Dr. Souweidane Named to NCI’s Brain Malignancies Steering Committee

Dr. Mark Souweidane, Weill Cornell Brain and Spine Center

The committee is charged with reviewing and prioritizing Phase 2 and Phase 3 clinical trial concepts, in order to promote the best clinical and translational research for patients with brain cancer.

Dr. Härtl Uses Adipose-Derived Stem Cells to Repair Herniated Disc

Weill Cornell Medicine - adipose derived stem cells ready for injection

Dr. Roger Härtl, director of spinal surgery at the Weill Cornell Brain and Spine Center and director of the Weill Cornell Medicine Center for Comprehensive Spine Care, recently performed an innovative procedure to repair a herniated disc using the patient’s own extracted and purified adipose (fat) tissue. The procedure, which took advantage of the high concentration of mesenchymal stem cells (MSCs) present in adipose tissue, has enormous potential for repairing herniated and degenerated discs.

Introducing “From the Annals of Weill Cornell Neurological Surgery”

From the Annals of Weill Cornell Neurosurgery

We are very happy to announce the first installment of “From the Annals of Weill Cornell Neurological Surgery” has been published in the October 2017 issue of World Neurosurgery.

Lyonhearted Foundation Funds New DIPG Project

Jason Lyon, Lyonhearted Foundation

Thanks to a gift from the Lyonhearted Foundation of southern California, Dr. Mark Souweidane and Dr. Uday Maachani will initiate a new research project in the Children’s Brain Tumor Project laboratory. The team expects the new investigation to validate the use of cell-free tumor  DNA (cf-DNA) as a biomarker of the disease burden in children with diffuse intrinsic pontine glioma (DIPG).